Combined treatment with FABP4 inhibitor ameliorates rosiglitazone-induced liver steatosis in obese diabetic db/db mice
文献类型：期刊论文
| 作者 | Chen, Meng-Ting1,2; Huang, Jun-Shang1,2; Gao, Ding-Ding3; Li, Ying-Xia3; Wang, He-Yao1,2
|
| 刊名 | BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
 |
| 出版日期 | 2021-06-15 |
| 页码 | 10 |
| ISSN号 | 1742-7835 |
| 关键词 | combined treatment FABP4 inhibitor liver steatosis obese type 2 diabetes rosiglitazone |
| DOI | 10.1111/bcpt.13621 |
| 通讯作者 | Wang, He-Yao(hywang@simm.ac.cn) |
| 英文摘要 | Rosiglitazone has been reported to exert dual effects on liver steatosis, and it could exacerbate liver steatosis in obese animal models, which was suggested to be closely related to the elevated hepatic expression of FABP4. This study aimed to investigate whether combined treatment with FABP4 inhibitor I-9 could alleviate rosiglitazone-induced liver steatosis in obese diabetic db/db mice. Male C57BL/KsJ-db/db mice were orally treated with rosiglitazone, rosiglitazone combined with I-9 daily for 8 weeks. The liver steatosis was evaluated by triglyceride content and H&E staining. The expression of hepatic lipogenic genes or proteins in liver tissue or in FFA-treated hepatocytes and PMA-stimulated macrophages were determined by real-time quantitative polymerase chain reaction (RT-qPCR) or western blotting. Results showed that combined treatment with I-9 decreased rosiglitazone-induced increase in serum FABP4 level and expression of lipogenic genes in liver, especially FABP4, and ameliorated liver steatosis in db/db mice. Rosiglitazone-induced intracellular TG accumulation and increased expression of FABP4 in the cultured hepatocytes and macrophages were also suppressed by combined treatment. We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy. |
| WOS关键词 | ACID-BINDING PROTEIN ; PPAR-GAMMA ; PEROXISOME PROLIFERATOR ; GENE-EXPRESSION ; FATTY LIVER ; NONALCOHOLIC STEATOHEPATITIS ; INSULIN-RESISTANCE ; HEPATIC STEATOSIS ; LIPID-METABOLISM ; GLUCOSE |
| 资助项目 | Ministry of Science and Technology of the People's Republic of China[2018ZX09711002-002-007] ; Chinese Academy of Sciences[XDA12040336] ; National Natural Science Foundation of China[81473262] ; National Natural Science Foundation of China[81773791] |
| WOS研究方向 | Pharmacology & Pharmacy ; Toxicology |
| 语种 | 英语 |
| 出版者 | WILEY |
| WOS记录号 | WOS:000661668000001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/297140]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wang, He-Yao |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, 555 Chong Zhi Rd, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Sch Pharm, Beijing, Peoples R China 3.Fudan Univ, Sch Pharm, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chen, Meng-Ting,Huang, Jun-Shang,Gao, Ding-Ding,et al. Combined treatment with FABP4 inhibitor ameliorates rosiglitazone-induced liver steatosis in obese diabetic db/db mice[J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY,2021:10. |
| APA | Chen, Meng-Ting,Huang, Jun-Shang,Gao, Ding-Ding,Li, Ying-Xia,&Wang, He-Yao.(2021).Combined treatment with FABP4 inhibitor ameliorates rosiglitazone-induced liver steatosis in obese diabetic db/db mice.BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY,10. |
| MLA | Chen, Meng-Ting,et al."Combined treatment with FABP4 inhibitor ameliorates rosiglitazone-induced liver steatosis in obese diabetic db/db mice".BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2021):10. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。